Dr. Gordon Srkalovic, MD

Dr. Srkalovic practices at UM Health-Sparrow Lansing Campus in Lansing, Michigan.

Dr. Srkalovic's NPI, 1780783282, was assigned on September 21, 2006. Dr. Srkalovic holds Michigan license 4301082787.

Dr. Srkalovic's primary practice is UM Health-Sparrow Lansing Campus, at 1215 E Michigan Ave, Lansing, MI 48912 in Ingham County. The practice phone is (517) 364-6000.

Dr. Srkalovic's primary practice is UM Health-Sparrow Lansing Campus in Lansing, Michigan. Dr. Srkalovic is also affiliated with University of Michigan Health-Sparrow Lansing. The medical group on file is University of Michigan Health-Sparrow. Dmand AI also links Dr. Srkalovic to 3 more hospitals and 4 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Srkalovic practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Srkalovic's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Srkalovic is licensed in Michigan.

CMS data shows 339 Medicare services from Dr. Srkalovic across 4 procedure codes in 2024, all of them office visits, for 166 Medicare patients. Medicare paid $19,686 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 166 Medicare patients who saw Dr. Srkalovic in 2024. The largest group is 65 to 74, with 80 patients. 67% of them have high blood pressure, and 58% have cancer. 14% are also on Medicaid. Their average risk score is 1.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Srkalovic's median patient age at 72, with 50% women.

In 2024, Dr. Srkalovic wrote 1,411 Medicare Part D claims for 203 patients. 70% of them were for generic drugs. CMS names the drug for 1,172 of them, across 40 drugs with 11 or more claims each, at $4,897,830 in total drug cost. In 2023, CMS named 1,159 claims across 38 drugs.

Dr. Srkalovic accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Srkalovic to 2 clinical trials. Conditions studied include Carcinoma, Non-Small-Cell Lung and Carcinoma, Bronchogenic.

CMS Open Payments shows 377 general payments to Dr. Srkalovic from 20 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 62% of the total. Janssen Pharmaceuticals, Inc paid the most, $188,642. It also lists 2 research payments totaling $212 from 2017 to 2018.